Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study
Background Immunotherapies targeting programmed cell death-1 (PD-1) and its ligands have improved clinical outcomes for advanced melanoma. However, many tumors exhibit primary resistance or acquire secondary resistance after an initial positive response. The mechanisms of resistance are not well und...
المؤلفون الرئيسيون: | Qing Zhao, Jeeyun Lee, Razvan Cristescu, Xiao Qiao Liu, Jennifer H. Yearley, Seung Tae Kim, Yuan Sun, Irene M. Shui, Tasmiah Choudhury, Andrea L. Webber, Clemens Krepler |
---|---|
التنسيق: | مقال |
اللغة: | English |
منشور في: |
BMJ Publishing Group
2022-07-01
|
سلاسل: | Journal for ImmunoTherapy of Cancer |
الوصول للمادة أونلاين: | https://jitc.bmj.com/content/10/7/e004879.full |
مواد مشابهة
-
Adjuvant and neoadjuvant immunotherapy for acral and mucosal melanoma
حسب: Takaya Komori, وآخرون
منشور في: (2025-01-01) -
Multidisciplinary approach and treatment of acral and mucosal melanoma
حسب: Ana Fortuna, وآخرون
منشور في: (2024-02-01) -
Genetic Characteristics of Cutaneous, Acral, and Mucosal Melanoma in Japan
حسب: Tokimasa Hida, وآخرون
منشور في: (2024-11-01) -
Editorial: Multidisciplinary treatment and precision medicine for acral and mucosal melanoma
حسب: Yu Xu, وآخرون
منشور في: (2024-05-01) -
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
حسب: Mario Sznol, وآخرون
منشور في: (2020-05-01)